Evidence map›Paper›PMID 36002021›Full record

ArticleJournal of molecular cell biology2022

CaMK4 overexpression in polycystic kidney disease promotes mTOR-mediated cell proliferation.

Yan Zhang, Emily A Daniel, July Metcalf, Yuqiao Dai, Gail A Reif, Darren P Wallace

Open access · goldAbstract read
In one paragraph

Article in Journal of molecular cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Integrative Transcriptomic and Proteomic Analysis RevealsAnimals : an open access journal from MDPI · 2025
    Article
  5. Article
  6. Review
  7. New Insights into the Regulation of mTOR Signaling via CaInternational journal of molecular sciences · 2023
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yan ZhangDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160-3018, USA.
Emily A DanielDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160-3018, USA.
July MetcalfDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160-3018, USA.
Yuqiao DaiDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160-3018, USA.
Gail A ReifDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160-3018, USA.
Darren P WallaceDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160-3018, USA.ORCID 0000-0003-4616-7669
University of Kansas Medical Center · US

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0M
Polycystin Function Resource Development CoreU54DK126126 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Alan S Yu · 2020 to 2026
$5.8M
Role of Periostin in Polycystic Kidney DiseaseR01DK081579 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WALLACE, DARREN P. · 2009 to 2018
$3.0M
NIDDK NIH HHS R01 DK081579NIDDK NIH HHS R01DK081579NIDDK NIH HHS U54 DK126126NIGMS NIH HHS P20 GM103418
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive enlargement of fluid-filled cysts, causing nephron loss and a decline in renal function. Mammalian target of rapamycin (mTOR) is overactive in cyst-lining cells and contributes to abnormal cell proliferation and cyst enlargement; however, the mechanism for mTOR stimulation remains unclear. We discovered that calcium/calmodulin (CaM) dependent kinase IV (CaMK4), a multifunctional kinase, is overexpressed in the kidneys of ADPKD patients and PKD mouse models. In human ADPKD cells, CaMK4 knockdown reduced mTOR abundance and the phosphorylation of ribosomal protein S6 kinase (S6K), a downstream target of mTOR. Pharmacologic inhibition of CaMK4 with KN-93 reduced phosphorylated S6K and S6 levels and inhibited cell proliferation and in vitro cyst formation of ADPKD cells. Moreover, inhibition of calcium/CaM-dependent protein kinase kinase-β and CaM, two key upstream regulators of CaMK4, also decreased mTOR signaling. The effects of KN-93 were independent of the liver kinase B1-adenosine monophosphate-activated protein kinase (AMPK) pathway, and the combination of KN-93 and metformin, an AMPK activator, had additive inhibitory effects on mTOR signaling and in vitro cyst growth. Our data suggest that increased CaMK4 expression and activity contribute to mTOR signaling and the proliferation of cystic cells of ADPKD kidneys.

Indexed as

CystsPolycystic Kidney, Autosomal DominantPolycystic Kidney DiseasesAMP-Activated Protein KinasesAnimalsBenzenesulfonamidesBenzylaminesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 4Cell ProliferationHumansKidneyMammalsMiceTOR Serine-Threonine KinasesAMP-Activated Protein KinasesBenzenesulfonamidesBenzylaminesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 4CAMK4 protein, humanCamk4 protein, mouseKN 93MTOR protein, humanTOR Serine-Threonine KinasesADPKDAMPKcalmodulinCaMK4CaMKKβLKB1

Identifiers

PMID36002021
PMCPMC9802383
OpenAlexW4293102400

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.